Q&A with Gilles Cottier, SAFC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Gilles Cottier, SAFC
A Q&A with Gilles Cottier, president of SAFC, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 1, pp. 81

PharmTech:



What is the biggest industry challenge you're now facing?

Cottier:

While companies always feel pressure to compete on pricing, the real pressure in the market comes as a result of the drive to provide and guarantee quality through process improvements and robust supply-chain security. Over the past few years, the market has seen a paradigm shift toward quality and supply-chain integrity. Demand to increase GMP compliance originated with regulatory bodies, but has been further emphasized by requests for compliance from customers and the industry as a whole. This shift in focus highlighted many issues, such as contamination, counterfeiting, and falsified documentation of pharmaceuticals and ingredients. The industry responded with a focus on accountability and a commitment to rectifying these matters and ensuring that offenders were held liable for their actions. It was encouraging to see the industry come together as a community to demand better quality for customers and, subsequently, the end-patient population. However, with these demands come pressures on suppliers and CMOs to meet these increasing quality requirements while keeping costs reasonable for customers.

PharmTech:

Do you see a new industry trend emerging?

Cottier:

As we continue to emerge from the economic downturn of the past couple of years, our industry as a whole has been forced to re-examine the way it does business. We have seen an increased focus on supply-chain transparency and quality. This problem has yet to be solved entirely, and the industry as a whole needs to continue to address it. Some companies offer increased transparency, but are still searching for cost–effective solutions. Transparency remains one of the major hurdles that the industry has yet to overcome.

Beyond that, the industry has been looking toward emerging markets and developing strategies to maximize market potential and positioning. SAFC has maintained a focus on identifying and participating in emerging markets to ensure that we are well-positioned to serve them.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here